Patent Application
20110021442
The present invention relates to cell permeable RUNX3 recombinant proteins in which a tumor and metastasis suppressor RUNX3 is fused to a macromolecule transduction domain (MTD), polynucleotides encoding the same, expression vectors for producing the same, and anticancer pharmaceutical compositions including the same as effective ingredients for treating RUNX3 deficiency or failure.
Gastric cancer is the most common cancer in Asian countries (e.g., Korea, Japan) and is the second most fatal disease worldwide. Therefore, it is very important to diagnose gastric cancer in its early stage. However, in the early stages of stomach cancer, the symptoms are vague and there is no characteristic symptom, making gastric cancer tricky to diagnose. Thus, a great deal of research on developing a fundamental treatment for gastric cancer through a comprehensive understanding of its pathogenesis has been actively carried out.
Recently, it has been reported that the reduction in expression of Runt-related transcription factor, RUNX3 relates to cancer development in the stomach (Li et al., Cell 109: 113-124, 2002). According to that report, a mouse model designed to have RUNX3 deficiency or failure in order to identify the function of RUNX3 developed gastric cancer due to the RUNX3 mutation.
Generally, if normal cells become old and diseased, they will die and new cells are generated on the spot. In RUNX3-deficient mice, these abnormal cells proliferate permanently, resulting in hyperplasia due to an increase in cell proliferation and a decrease in cell death. However, p53-deficient mice with normal RUNX3 did not develop gastric cancer (Li et al., Cell 109: 113-124, 2002). These results suggest that RUNX3 plays an important role in regulating cell proliferation and that the inactivation of RUNX3 may be a potential cause of gastric cancer. In fact, based on an analysis of the examination of gastric cancer cells and tissues to confirm the inhibitory effect of RUNX3 on gastric cancer, a close relationship has been found to exist between RUNX3 and gastric cancer. In particular, in analyzing tissues of 46 gastric cancer patients, hemizygous deletion of RUNX3 was detected in 30% of the patients, where RUNX3 was inactivated in about 45˜60% of those patients due to hypermethylation of CpG islands located at the RUNX3 promoter (Li et al., Cell 109: 113-124, 2002; Waki et al., Cancer Sci. 94: 360-364, 2003).
The RUNT-domain family of transcription factors known as polyomavirus enhancer binding protein 1/core binding factors (PEBP2/CBF) is composed of RUNX1 (PEBP2αB/CBFA2/AML1), RUNX2 (PEBP2αA/CBFA1/AML3) and RUNX3 (PEBP2αC/CBFA3/AML2). The RUNT-domain family is a key player in normal development and oncogenesis and, for instance, functions as a transcription factor for the Smad family which is a subunit capable of mediating TGF-β and the signal transduction thereof. RUNX1 is essential for definitive haematopoiesis in mammals, while RUNX2 promotes osteogenesis and cell differentiation and RUNX3 mainly expressed in granular gastric mucous cells functions to inhibit epithelial cell differentiation. These three members are located on chromosomes 1p, 6p, and 21 q, respectively, and the chromosomal locus of RUNX3 is 1p36.11-1p36.13. The RUNX3 locus is commonly deleted in a variety of human cancers, including gastric cancer, pancreatic cancer, lung cancer, colon cancer, liver cancer and the like, and is a site that is easily subject to hemizygous deletion. Further, it has been found that RUNX3 is inactivated in a number of the above listed human cancers, suggesting that RUNX3 is a promising target for the development of a new anticancer drug.
It has been also reported that RUNX3 is capable of not only inhibiting tumor growth as a tumor suppressor but also suppressing metastasis. RUNX3 inhibits the expression of vascular endothelial growth factor (VEGF) which is involved in the formation of blood vessels essential for cancer metastasis (Keping Xie et al., Cancer Res. 65:4809-5816, 2006), while cancer metastasis in a RUNX3-transgenic mouse is further suppressed as compared with a control (Hagiwara et al., Clin Cancer Res. 11(18): 6479-6488, 2005).
When RUNX3 stimulates a signal transduction pathway of TGF-β, the thus stimulated TGF-β induces the activation of Smad2/3. After the TGF-β-induced activation, Smad2/3 interacts with Smad4 and transfers into the nucleus in a complex form, followed by binding to p300 and RUNX3. Consequently, the transcription of a target gene is induced and apoptosis occurrs.
It has been known that TGF-β is involved in many development processes and physiological activities as a cell growth regulator. A TGF-β receptor and its signal transduction protein Smad are usually inactivated in various different cancers (Cohen et al., Am. J. Med. Genet. 116A: 1-10, 2003). It has also been reported that p300 involved in the TGF-β signal transduction pathway, in combination with Smad, is mutated in a variety of cancers (Gayther et al., Nat. Genet. 24: 300-303. 2000). RUNX3 present in the nucleus interacts with both Smad and p300 involved in the TGF-β signal transduction pathway and cooperatively acts as a tumor and metastasis suppressor (Hanai et al., J. Biol. Chem. 274: 31577-1582. 1999; Kitabayashi et al., EMBO J. 17: 2994-3004. 1998; Lee et al., Mol. Cell. Biol. 20: 8783-8792, 2000; Zhang et al., Proc. Natl. Acad. Sci. USA. 97: 10549-10554, 2000).
TGF-β also inhibits cell proliferation by blocking the G1 phase of the cell cycle (Sherr et al., Science 274: 1672-677, 1996; Weinberg et al., Cell 81: 323-30, 1995). When RUNX3 that has gone through the TGF-β signal transduction pathway forms a complex with Smad2, Smad4, p300, and the like in the nucleus while the expression of p21 which inhibits the cell cycle increases, the phosphorylation of Cyclin A, Cyclin E, PCNA, and Rb regulating the cell cycle, as well as the expression of VEGF responsible for metastasis, is suppressed, leading to the inhibition of metastasis.
Thus considering that it would be possible to effectively suppress tumor growth and metastasis if the overexpression of RUNX3 is induced in vivo or RUNX3 is directly delivered into the cells, the present inventors endeavored to develop new anticancer agents by using the RUNX3 protein.
Meanwhile, small molecules derived from synthetic compounds or natural compounds can be transported into the cells, whereas macromolecules, such as proteins, peptides, and nucleic acids, cannot. It is widely understood that macromolecules larger than 500 kDa are incapable of penetrating the plasma membrane, i.e., the lipid bilayer structure, of live cells. To overcome this problem, a “macromolecule intracellular transduction technology (MITT)” was developed (Jo et al., Nat. Biotech. 19: 929-33, 2001), which allows the delivery of therapeutically effective macromolecules into cells, making the development of new drugs using peptides, proteins and genetic materials possible. According to this method, if a target macromolecule is fused to a hydrophobic macromolecule transduction domain (MTD) and other cellular delivery regulators, synthesized, expressed, and purified in the form of a recombinant protein, it can penetrate the plasma membrane lipid bilayer of the cells, be accurately delivered to a target site, and then, effectively exhibit its therapeutic effect. Such MTDs facilitate the transport of many impermeable materials which are fused to peptides, proteins, DNA, RNA, synthetic compounds, and the like into the cells.
Accordingly, the inventors of the present invention have developed a method of mediating the transport of a tumor and metastasis suppressor RUNX3 into the cells, where cell permeable RUNX3 recombinant proteins are engineered by fusing a MTD to the tumor and metastasis suppressor RUNX3. Such cell permeable RUNX3 recombinant proteins have been found to efficiently mediate the transport of the tumor and metastasis suppressor RUNX3 into the cells in vivo as well as in vitro and can be used as anticancer agents for inhibiting metastasis occurring in various human cancers.
Accordingly, the objective of the present invention is to provide cell permeable RUNX3 recombinant proteins effective for the treatment of RUNX3 deficiency or failure occurring in various kinds of human cancers as anticancer agents.
One aspect of the present invention relates to cell permeable RUNX3 recombinant proteins capable of mediating the transport of a tumor and metastasis suppressor RUNX3 into a cell by fusing a macromolecule transduction domain (MTD) having cell permeability to the tumor and metastasis suppressor protein.
Another aspect of the present invention relates to polynucleotides encoding the above cell permeable RUNX3 recombinant proteins.
The present invention also relates to expression vectors containing the above polynucleotides, and transformants transformed with the above expression vectors.
Another aspect of the present invention relates to a method of producing cell permeable RUNX3 recombinant proteins involving culturing the above transformants.
Another aspect of the present invention relates to a pharmaceutical composition including the above cell permeable RUNX3 recombinant proteins as an effective ingredient for treating RUNX3 deficiency or failure.
The cell permeable RUNX3 recombinant proteins of the present invention can induce the reactivation of TGF-β signal transduction pathway which causes cell cycle arrest by efficiently introducing a tumor and metastasis suppressor RUNX3 into a cell. Therefore, the cell permeable RUNX3 recombinant proteins of the present invention can be effectively used as an anticancer agent capable of preventing cancer growth and metastasis by suppressing the proliferation, differentiation, and migration of cancer cells.
a is a schematic diagram illustrating the structures of cell permeable RUNX3 recombinant proteins being fused to a kFGF4-derived MTD and constructed in the full-length and truncated forms according to the present invention.
b is a schematic diagram illustrating the structures of cell permeable RUNX3 recombinant proteins being fused to one of JO-57, JO-85, JO-13 and JO-108 MTDs, and constructed in the full-length form according to the present invention.
a is a photograph of an agarose gel electrophoresis analysis showing PCR-amplified DNA fragments encoding cell permeable RUNX3 recombinant proteins being fused to a kFGF4-derived MTD and constructed in the full-length and truncated forms according to the present invention.
b is a photograph of an agarose gel electrophoresis analysis showing PCR-amplified DNA fragments encoding cell permeable RUNX3 recombinant proteins being fused to one of JO-57, JO-85, JO-13 and JO-108 MTDs, and constructed in the full-length and truncated forms according to the present invention.
a is a schematic diagram illustrating the subcloning of a PCR product encoding a cell permeable RUNX3 recombinant protein into the pGEM-T Easy vector according to the present invention.
b and 3c are photographs of an agarose gel electrophoresis analysis showing the PCR products encoding the cell permeable RUNX3 recombinant proteins subcloned in the pGEM-T Easy vector according to the present invention, respectively.
a is a schematic diagram illustrating the cloning of a recombinant DNA fragment encoding a cell permeable RUNX3 recombinant protein into the pET-28(+) vector according to the present invention.
b and 4c are photographs of an agarose gel electrophoresis analysis showing the recombinant DNA fragments encoding the cell permeable RUNX3 recombinant proteins subcloned in the pET-28(+) vector according to the present invention, respectively.
a is a photograph of a SDS-PAGE analysis showing the inducible expression of cell permeable RUNX3 recombinant proteins according to the present invention in various kinds of host cells.
b is a photograph of a SDS-PAGE analysis showing the inducible expression of cell permeable RUNX3 recombinant proteins according to the present invention in the presence (+) or the absence (−) of IPTG as an inducer.
a and 6b are photographs of a SDS-PAGE analysis showing the purification of cell permeable RUNX3 recombinant proteins (HM1R3, HR3M1, HM1R3M1, HM2R3 and HM3R3) expressed from the transformants where the expression vector according to the present invention is transformed into.
a and 7b are graphs illustrating the results of flow cytometry analysis of cell permeabilities of cell permeable RUNX3 recombinant proteins (HM1R3, HR3M1, HM1R3M1 and HM3R3) according to the present invention.
a and 10b are photographs of a Western blot analysis showing the in vivo function of cell permeable RUNX3 recombinant proteins (HM1R3M1, HM2R3 and HM3R3) according to the present invention.
a and 12b are photographs of a wound healing assay showing the inhibitory effect of cell permeable RUNX3 recombinant proteins (HM1R3M1, HM2R3 and HM3R3) according to the present invention on tumor cell migration.
a and 13b are graphs illustrating the change in tumor size and body weight, respectively, in a tumor-bearing mouse where each of cell permeable RUNX3 recombinant proteins (HM2R3 and HM3R3) according to the present invention was administered via subcutaneous injection for 26 days.
The present invention provides cell permeable RUNX3 recombinant proteins (CP-RUNX3) capable of mediating the transport of a tumor and metastasis suppressor RUNX3 into a cell in which the tumor and metastasis suppressor RUNX3 is fused to a macromolecule transduction domain (MTD) and, thereby, imparted with cell permeability; and polynucleotides encoding each of the cell permeable RUNX3 recombinant proteins.
The present invention is characterized in that a tumor and metastasis suppressor RUNX3 which is a macromolecule incapable of being introduced into a cell is fused to a specific macromolecule transduction domain (hereinafter, “MTD”) peptide so as to provide cell permeability, and thus, can be effectively transported into a cell. The MTD peptide may be fused to the N-terminus, the C-terminus, or both termini of the tumor and metastasis suppressor RUNX3.
The present invention has developed cell permeable RUNX3 recombinant proteins that are engineered by fusing a tumor and metastasis suppressor RUNX3 to one of five MTD domains capable of mediating the transport of a macromolecule into a cell.
The term “cell permeable RUNX3 recombinant protein” as used herein refers to a covalent bond complex bearing a MTD and a tumor and metastasis suppressor protein RUNX3, where they are functionally linked by genetic fusion or chemical coupling. Here, the term “genetic fusion” refers to a co-linear, covalent linkage of two or more proteins or fragments thereof via their individual peptide backbones, through genetic expression of a polynucleotide molecule encoding those proteins.
RUNX3 is a tumor and metastasis suppressor protein that activates p21, which inhibits the cell cycle and induces apoptosis, and suppresses VEGF which induces metastasis. RUNX3 has an amino acid sequence represented by SEQ ID NO: 2, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 1. RUNX3 functions as an important target protein in the TGF-β signal transduction pathway.
The amino acid sequence of the tumor and metastasis suppressor RUNX3, i.e., SEQ ID NO: 2, is composed of a N-terminal domain corresponding to amino acid residues 1-53, a R-terminal domain corresponding to amino acid residues 54-182, and a PST-rich domain corresponding to amino acid residues 183-414 (see
For the MTD capable of being fused to the tumor and metastasis suppressor
RUNX3, cell permeable peptides having an amino acid sequence selected from the group consisting of SEQ ID NOS: 3 to 196 may be used. The MTD having one of the amino acid sequences represented by SEQ ID NOS: 3 to 196 is a cell permeable polypeptide which is capable of mediating the transport of a biologically active molecule, such as a polypeptide, a protein domain, or a full-length protein across the cell membrane. Suitable MTDs for the present invention include a hydrophobic region showing cell membrane targeting activity by forming a helix structure at a signal peptide which is composed of an N-terminal domain, a hydrophobic domain and a C-terminal domain containing a secreted protein cleavage site. These MTDs can directly penetrate the cell membrane without causing any cell damage, transport a target protein into a cell, and thus, allow the target protein to exhibit its desired function.
The MTDs having the amino acid sequences represented by SEQ ID NOS: 3 to 196 and capable of being fused to a tumor and metastasis suppressor RUNX3 according to the present invention are summarized in the following Tables 1a to 1i.
coelicolorA3(2)]
bovis AF2122/97]
coelicolor A3(2)]
sapiens]
musculus]
serovar Typhi]
spatzle (spz) gene
sapiens]
Xenopsin precursor fragment (XPF);
Xenopsin]
[Theileria annulata]
bovis AF2122/97]
Mus musculus
Homo sapiens
sapiens]
meningitidis Z2491]
In some embodiments, the present invention may employ a kaposi fibroblast growth factor 4 (kFGF4)-derived MTD having the amino acid sequence of SEQ ID NO: 3 (hereinafter, “MTD1”), a JO-57 MTD having the amino acid sequence of SEQ ID NO: 60 which is a hypothetical protein derived from Salmonella enterica subsp. (hereinafter, “MTD2”), a JO-85 MTD having the amino acid sequence of SEQ ID NO: 88 which is a peptide binding protein derived from Streptomyces coelicolor (hereinafter, “MTD3”), a JO-13 MTD having the amino acid sequence of SEQ ID NO: 16 which is a putative secreted protein derived from Streptomyces coelicolor (hereinafter, “MTD4”), and a JO-108 MTD having the amino acid sequence of SEQ ID NO: 111 which is a cellular repressor derived from Homo sapiens (hereinafter, “MTD5”), as the MTD capable of mediating the transport of the tumor and metastasis suppressor RUNX3 into a cell.
The cell permeable RUNX3 recombinant proteins according to the present invention have a structure where one of the five MTDs (kFGF4-derived MTD: MTD1, JO-57: MTD2, JO-85: MTD3, JO-13: MTD4, JO-108: MTD5) is fused to one terminus or both termini of a tumor and metastasis suppressor protein RUNX3, and a SV40 large T antigen-derived nuclear localization sequence (NLS) and a histidine-tag (His-Tag) affinity domain for easy purification are fused to one terminus of the resulting construct.
In another embodiment, the present invention relates to the construction of three full-length forms and six truncated forms of a cell permeable RUNX3 recombinant protein by using a kFGF4-derived MTD.
As used herein, the term “full-length form” refers to a construct including the entire N-terminal, R-terminal, and PST-rich domains of the tumor and metastasis suppressor protein RUNX3, while the term “truncated form” refers to a construct lacking any one or more of the N-terminal, R-terminal, and PST-rich domains thereof.
Referring to
As for the full-length forms of the cell permeable RUNX3 recombinant protein constructed by using a kFGF4-derived MTD as described above, HM1R3 has an amino acid sequence represented by SEQ ID NO: 199, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 198; HR3M1 has an amino acid sequence represented by SEQ ID NO: 201, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 200; and HM1R3M1 has an amino acid sequence represented by SEQ ID NO: 203, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 202.
Further, the truncated forms of the cell permeable RUNX3 recombinant protein are as follows:
As for the truncated forms of the cell permeable RUNX3 recombinant protein as described above, HR3NM1 has an amino acid sequence represented by SEQ ID NO: 205, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 204; HR3RM1 has an amino acid sequence represented by SEQ ID NO: 207, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 206; HR3PM1 has an amino acid sequence represented by SEQ ID NO: 209, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 208; HR3NRM1 has an amino acid sequence represented by SEQ ID NO: 211, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 210; HR3PRM1 has an amino acid sequence represented by SEQ ID NO: 213, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 212; and HR3CRM1 has an amino acid sequence represented by SEQ ID NO: 215, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 214.
In another embodiment, the present invention relates to the construction of three full-length forms of a cell permeable RUNX3 recombinant protein by using a JO-57 MTD, a JO-85 MTD, a JO-13 MTD and a JO-108 MTD, respectively.
Referring to
Further, the full-length forms of the cell permeable RUNX3 recombinant protein constructed by using a JO-85 MTD are as follows:
Further, the full-length forms of the cell permeable RUNX3 recombinant protein constructed by using a JO-13 MTD are as follows:
Further, the full-length forms of the cell permeable RUNX3 recombinant protein constructed by using a JO-108 MTD are as follows:
As for the full-length forms of the cell permeable RUNX3 recombinant protein constructed by using a JO-57 MTD as described above, HM2R3 has an amino acid sequence represented by SEQ ID NO: 217, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 216; HR3M2 has an amino acid sequence represented by SEQ ID NO: 219, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 218; and HM2R3M2 has an amino acid sequence represented by SEQ ID NO: 221, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 220.
As for the full-length forms of the cell permeable RUNX3 recombinant protein constructed by using a JO-85 MTD as described above, HM3R3 has an amino acid sequence represented by SEQ ID NO: 223, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 222; HR3M3 has an amino acid sequence represented by SEQ ID NO: 225, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 224; and HM3R3M3 has an amino acid sequence represented by SEQ ID NO: 227, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 226.
As for the full-length forms of the cell permeable RUNX3 recombinant protein constructed by using a JO-13 MTD as described above, HM4R3 has an amino acid sequence represented by SEQ ID NO: 229, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 228; HR3M4 has an amino acid sequence represented by SEQ ID NO: 231, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 230; and HM4R3M4 has an amino acid sequence represented by SEQ ID NO: 233, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 232.
As for the full-length forms of the cell permeable RUNX3 recombinant protein constructed by using a JO-108 MTD as described above, HM5R3 has an amino acid sequence represented by SEQ ID NO: 235, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 234; HR3M5 has an amino acid sequence represented by SEQ ID NO: 237, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 236; and HM5R3M5 has an amino acid sequence represented by SEQ ID NO: 239, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 238.
As a control for the cell permeable RUNX3 recombinant proteins, HR3, where a full-length RUNX3 is fused only to a NLS derived from SV40 large T antigen and a histidine-tag (His-Tag) without any MTD, is constructed. The control protein has an amino acid sequence represented by SEQ ID NO: 241, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 240.
Further, the present invention provides an expression vector containing the polynucleotide encoding each of the cell permeable RUNX3 recombinant proteins described above, and a transformant capable of producing each of the cell permeable RUNX3 recombinant proteins at high levels, which is obtainable by transforming a host cell using the expression vector.
As used herein, the term “expression vector” is a vector capable of expressing a target protein or a target RNA in a suitable host cell. The nucleotide sequence of the present invention may be present in a vector in which the nucleotide sequence is operably linked to regulatory sequences capable of providing for the expression of the nucleotide sequence by a suitable host cell.
Within an expression vector, the term “operably linked” is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence. The term “regulatory sequence” is intended to include promoters, enhancers, and other expression control elements. Such operable linkage with the expression vector can be achieved by conventional gene recombination techniques known in the art, while site-directed DNA cleavage and linkage are carried out by using conventional enzymes known in the art.
The expression vectors suitable for the present invention may include plasmid vectors, cosmid vectors, bacteriophage vectors, viral vectors and the like, but are not limited thereto. The expression vectors for use in the present invention may contain a signal sequence or a leader sequence for membrane targeting or secretion, as well as regulatory sequences such as a promoter, an operator, an initiation codon, a termination codon, a polyadenylation signal, an enhancer and the like. The promoter may be a constitutive or an inducible promoter. Further, the expression vector may include one or more selectable marker genes for selecting the host cell containing the expression vector, and may further include a nucleotide sequence that enables the vector to replicate in the host cell in question.
The expression vector constructed according to the present invention may be exemplified by pHR3M1 where the polynucleotide encoding the recombinant protein HR3M1 where a kFGF4-derived MTD is fused to the C-terminus of a full-length RUNX3 is inserted into a cleavage site of NdeI restriction enzyme within the multiple cloning sites (MCS) of a pET-28a(+) vector.
In another embodiment, the polynucleotide of the present invention is cloned into a pET-28a(+) vector (Novagen, Germany) bearing a His-tag sequence so as to fuse six histidine residues to the N-terminus of the cell permeable RUNX3 recombinant protein to allow easy purification.
Accordingly, the cell permeable RUNX3 recombinant protein expressed in the above expression vector has a structure where one of a kFGF4-derived MTD, a JO-57 MTD, a JO-85 MTD, a JO-13 MTD and a JO-108 MTD is fused to the full-length or truncated RUNX3, and a His-tag and NLS are linked to the N-terminus thereof.
The present invention further provides a transformant capable of producing each of the cell permeable RUNX3 recombinant proteins at high levels which is obtainable by transforming a host cell using the expression vector. The host cell suitable for the present invention may be eukaryotic cells, such as E. coli. In one embodiment of the present invention, E. coli used as a host cell is transformed with the expression vector, for example, pHR3M1 containing the polynucleotide encoding the cell permeable recombinant protein HR3M1 where a kFGF4-derived MTD is fused to the C-terminus of a full-length RUNX3 according to the present invention so as to produce the cell permeable RUNX3 recombinant protein at high levels. Methods for transforming bacterial cells are well known in the art, and include, but are not limited to, biochemical means such as transformation, transfection, conjugation, protoplast fusion, calcium phosphate-precipitation, and application of polycations such as diethylaminoethyl (DEAE) dextran, and mechanical means such as electroporation, direct microinjection, microprojectile bombardment, calcium phosphate (CaPO4) precipitation, calcium chloride (CaCl2) precipitation, PEG-mediated fusion and liposome-mediated method.
In some embodiments, the transformants DH5α/HM2R3 and DH5α/HM3R3 obtained by transforming E. coli DH5α with the expression vector containing the cell permeable RUNX3 recombinant protein HM2R3 where a JO-57 MTD is fused to the N-terminus of a full-length RUNX3, and the expression vector containing the cell permeable RUNX3 recombinant protein HM3R3 where a JO-85 MTD is fused to the C-terminus thereof, respectively, were deposited under accession numbers KCTC-11408BP and KCTC-11409BP, respectively, with the Korean Collection for Type Cultures (KCTC), Korea Research Institute of Bioscience and Biotechnology (KRIBB), 52, Oun-Dong, Yusong-Ku, Taejon 305-333, Republic of Korea. All deposits referred to herein were made on Oct. 29, 2008 in accordance with the Budapest Treaty, and all restrictions imposed by the depositor on the availability to the public of the deposited biological material will be irrevocably removed upon the granting of the patent.
The present invention provides a method of producing the cell permeable RUNX3 recombinant proteins at high levels, which includes the step of culturing the above transformant.
The method of the present invention may be carried out by culturing the transformant in a suitable medium under suitable conditions for expressing a cell permeable RUNX3 recombinant protein of the present invention in the expression vector introduced into the transformant. Methods for expressing a recombinant protein by culturing a transformant are well known in the art, and for example, may be carried out by inoculating a transformant in a suitable medium for growing the transformant, performing a subculture, transferring the same to a main culture medium, culturing under suitable conditions, for example, supplemented with a gene expression inducer, isopropyl-β-D-thiogalactoside (IPTG) and, thereby, inducing the expression of a recombinant protein. After the culture is completed, it is possible to recover a “substantially pure” recombinant protein from the culture solution. The term “substantially pure” means that the recombinant protein and polynucleotide encoding the same of the present invention are essentially free of other substances with which they may be found in nature or in vivo systems to the extent practical and appropriate for their intended use.
A recombinant protein of the present invention obtained as above may be isolated from the inside or outside (e.g., medium) of host cells, and purified as a substantially pure homogeneous polypeptide. The method for polypeptide isolation and purification is not limited to any specific method. In fact, any standard method may be used. For instance, chromatography, filters, ultrafiltration, salting out, solvent precipitation, solvent extraction, distillation, immunoprecipitation, SDS-polyacrylamide gel electrophoresis, isoelectric point electrophoresis, dialysis, and recrystallization may be appropriately selected and combined to isolate and purify the polypeptide. As for chromatography, affinity chromatography, ion-exchange chromatography, hydrophobic chromatography, gel filtration chromatography, reverse phase chromatography, adsorption chromatography, etc., for example, may be used (Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1982; Sambrook et al., Molecular Cloning: A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, 1989; Deutscher, M., Guide to Protein Purification Methods Enzymology vol. 182. Academic Press. Inc., San Diego, Calif., 1990).
Meanwhile, the recombinant protein expressed in the transformants according to the present invention can be classified into a soluble fraction and an insoluble fraction according to protein characteristics during the protein purification process. If the majority of the expressed recombinant proteins are present in the soluble fraction, the recombinant protein can be isolated and purified according to the method as described above. However, when the majority of the expressed recombinant proteins are present in the insoluble fraction, i.e., as inclusion bodies, the recombinant proteins are first solubilized by using polypeptide denaturing agents, e.g., urea, guanidine HCl, or detergents, and then, purified by performing a series of centrifugation, dialysis, electrophoresis and column chromatography. Since there is the risk of losing the recombinant protein's activity due to a structural modification caused by the polypeptide denaturing agent, the process of purifying the recombinant protein from the insoluble fraction requires desalting and refolding steps. That is, the desalting and refolding steps can be performed by dialysis and dilution with a solution that does not include a polypeptide denaturing agent or by centrifugation with a filter. Further, if a salt concentration of the solution used for the purification of a recombinant protein from a soluble fraction is relatively high, such desalting and refolding steps may be performed.
In some embodiments, it has been found that the cell permeable RUNX3 recombinant protein of the present invention mostly exists in the insoluble fraction as an inclusion body. In order to purify the recombinant protein from the insoluble fraction, the insoluble fraction may be dissolved in a lysis buffer containing a non-ionic surfactant such as Triton X-100, subjected to ultrasonification, and then centrifuged to separate a precipitate. The separated precipitate may be dissolved in a buffer supplemented with a strong denaturing agent, such as urea, and centrifuged to separate the supernatant. The above separated supernatant is purified by means of a histidin-tagged protein purification kit and subjected to ultrafiltration, for example, by using an amicon filter for salt removal and protein refolding, thereby obtaining a purified recombinant protein of the present invention.
Further, the present invention provides an anticancer pharmaceutical composition comprising the cell permeable RUNX3 recombinant protein as an effective ingredient for treating RUNX3 deficiency or failure.
The cell permeable RUNX3 recombinant proteins of the present invention can reactivate a TGF-β signal transduction pathway by efficiently introducing a tumor and metastasis suppressor protein RUNX3 into a cell when the protein is deficient or its function is lost. Therefore, the cell permeable RUNX3 recombinant proteins of the present invention can be effectively used as an anticancer agent capable of preventing and/or treating cancer growth and metastasis.
The pharmaceutical composition comprising the recombinant protein of the present invention as an effective ingredient may further include pharmaceutically acceptable carriers suitable for oral administration or parenteral administration. As used herein, “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drugs, drug stabilizers, gels, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, such like materials and combinations thereof, as would be known to one of ordinary skill in the art (Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, Pa., 1995). The carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid and the like. In case of oral administration, the recombinant protein of the present invention can be formulated in the form of chewable tablets, buccal tablets, troches, capsules, elixir, suspensions, syrup, wafers or combination thereof by mixing with the carriers. Further, the carriers for parenteral administration may include water, suitable oil, saline, aqueous glucose, glycol and the like, and may further include stabilizers and preservatives. The stabilizers suitable for the present invention may include antioxidants such as sodium bisulfite, sodium sulfite and ascorbic acid. Suitable preservatives may include benzalconium chloride, methly-paraben, propyl-paraben and chlorobutanol.
The pharmaceutical composition of the present invention may be formulated into various parenteral or oral administration forms. Representative examples of the parenteral formulation include those designed for administration by injection. For injection, the recombinant proteins of the present invention may be formulated in aqueous solutions, specifically in physiologically compatible buffers or physiological saline buffer. These injection formulations may be formulated by conventional methods using one or more dispersing agents, wetting agents and suspending agents. For oral administration, the proteins can be readily formulated by combining the proteins with pharmaceutically acceptable carriers well known in the art. Such carriers enable the proteins of the invention to be formulated as tablets, pills, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Such oral solid formulations may include suitable excipients such as diluents (e.g., lactose, dextrose, sucrose, mannitol, sorbitol cellulose and/or glycin) and lubricants (e.g., colloidal silica, talc, stearic acid, magnesium stearate, calcium stearate, and/or polyethylene glycol). The tablets may include binders, such as aluminum silicate, starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP), and disintegrating agents, such as cross-linked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. If desired, absorbents, coloring agents, flavoring agents and/or sweeteners may be added. The formulations can be prepared by mixing, granulating or coating according to conventional methods well-known in the art.
If necessary, the pharmaceutical compositions of the present invention may further include pharmaceutical additives, such as preservatives, antioxidants, emulsifiers, buffering agents and/or salts for regulating osmosis and other therapeutically effective materials, and can be formulated according to conventional methods known in the art.
In addition, the pharmaceutical composition of the present invention can be administered via oral routes or parenteral routes such as intravenously, subcutaneously, intranasally or intraperitoneally. The oral administration may include sublingual application. The parenteral administration may include drip infusion and injection such as subcutaneous injection, intramuscular injection, intravenous injection and introtumoral injection.
The total effective amount of the recombinant protein of the present invention can be administered to patients in a single dose or can be administered by a fractionated treatment protocol, in which multiple doses are administered over a more prolonged period of time. Although the amount of the recombinant protein or nucleic acid encoding the same in the pharmaceutical composition of the present invention may vary depending on the severity of diseases, the protein or the nucleic acid may be generally administered several times a day at an effective dose of 5 to 20 mg. However, a suitable dose of the recombinant protein in the pharmaceutical composition of the present invention may depend on many factors, such as age, body weight, health condition, sex, disease severity, diet and excretion of patients, as well as the route of administration and the number of treatments to be administered. In view of the above factors, any person skilled in the art may determine the effective dose of the recombinant protein as an anti-metastatic agent for preventing metastasis in various human cancers. The pharmaceutical composition of the present invention containing the recombinant protein has no special limitations on its formulation, administration route and/or administration mode insofar as it exhibits the effects of the present invention.
The following examples are provided to illustrate the embodiments of the present invention in more detail, but are by no means intended to limit its scope.
1-1>Construction of Cell Permeable RUNX3 Recombinant Proteins Using a kFGF4-Derived MTD
Three full-length forms and six truncated forms of a cell permeable RUNX3 recombinant protein were constructed by using a kFGF4-derived MTD (MTD1).
Referring to
In order to prepare the full-length CP-RUNX3 recombinant constructs, polymerase chain reactions (PCRs) were carried out by using the oligonucleotides as a primer pair specific for each recombinant construct and a human RUNX3 cDNA as a template. The forward and reverse primers for amplifying HM1R3 have nucleotide sequences represented by SEQ ID NOS: 244 and 243, respectively; those for amplifying HR3M1 have nucleotide sequences represented by SEQ ID NOS: 242 and 245, respectively; and those for amplifying HM1R3M1 have nucleotide sequences represented by SEQ ID NOS: 244 and 245, respectively.
Further, the truncated forms of a CP-RUNX3 recombinant protein were as follows:
In order to prepare the truncated CP-RUNX3 recombinant proteins, PCR was carried out by using the oligonucleotides as a primer set specific for each recombinant protein and a human RUNX3 cDNA as a template. The forward and reverse primers for amplifying HR3NM1 have nucleotide sequences represented by SEQ ID NOS: 246 and 247, respectively; while those for amplifying HR3RM1 have nucleotide sequences represented by SEQ ID NOS: 248 and 249, respectively; those for amplifying HR3PM1 have nucleotide sequences represented by SEQ ID NOS: 250 and 245, respectively; those for amplifying HR3NRM1 have nucleotide sequences represented by SEQ ID NOS: 246 and 249, respectively; those for amplifying HR3RPM1 have nucleotide sequences represented by SEQ ID NOS: 248 and 245, respectively; and those for amplifying HR3CRM1 have nucleotide sequences represented by SEQ ID NOS: 251 and 252, respectively
The PCR was performed in a 50 μl reaction mixture containing 100 ng of human RUNX3 cDNA (College of Medicine, Chungbuk National University) as a template, 0.2 mM dNTP mixture, 1 μM of each primer, 5 μl of 10× Taq buffer, 1 μl of Taq polymerase (Novagen, Germany). The PCR was performed for 25 cycles at 94° C. for 20 seconds, at 63° C. for 30 seconds and at 72° C. for 30 seconds after the initial denaturation of 94° C. for 5 minutes, followed by the final extension at 72° C. for 5 minutes. After the PCR was completed, the amplified PCR product was digested with restriction enzyme NdeI and loaded onto a 1.0% agarose gel and fractionated.
As shown in
The DNA band of expected size was excised from the gel, eluted, and purified by using a QIAquick Gel extraction kit (Qiagen, USA). The eluted DNA was precipitated with ethanol and resuspended in distilled water for ligation. As shown in
As shown in
A pET-28(+)a vector (Novagen, Germany) bearing a histidine-tag and a T7 promoter was digested with a restriction enzyme NdeI for 1 hour at 37° C. The pGEM-T Easy vector fragments containing the CP-RUNX3 recombinant fragment and pET-28(+)a vector fragment were purified by using a QIAquick Gel extraction kit. Each of the pGEM-T Easy vector fragments was cloned into the pre-treated pET-28a(+) with a T4 ligase at 16 r for 12 hours, followed by transformation of E. coli DH5α competent cells with the resulting pET-28a(+) vector (
After the clones were treated with the restriction enzyme NdeI (Enzynomics, Korea) and subjected to 0.8% agarose gel electrophoresis, it was verified that the cloning of the insert DNA of CP-RUNX3 recombinant construct into pET-28a(+) vector, as shown in
The successfully cloned expression vectors for expressing cell permeable RUNX3 recombinant proteins were designated pHM1R3, pHR3M1, pHM1R3M1, pHR3NM1, pHR3RM1, pHR3PM1, pHR3NRM1, pHR3RPM1, and pHR3CRM1, respectively.
The results of sequencing analysis are as follows:
As for the full-length forms of the cell permeable RUNX3 recombinant protein as described above, HM1R3 has an amino acid sequence represented by SEQ ID NO: 199, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 198; HR3M1 has an amino acid sequence represented by SEQ ID NO: 201, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 200; and HM1R3M1 has an amino acid sequence represented by SEQ ID NO: 203, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 202.
As for the truncated forms of the cell permeable RUNX3 recombinant protein as described above, HR3NM1 has an amino acid sequence represented by SEQ ID NO: 205, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 204; HR3RM1 has an amino acid sequence represented by SEQ ID NO: 207, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 206; HR3PM1 has an amino acid sequence represented by SEQ ID NO: 209, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 208; 1-1R3NRM1 has an amino acid sequence represented by SEQ ID NO: 211, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 210; HR3PRM1 has an amino acid sequence represented by SEQ ID NO: 213, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 212; and HR3CRM1 has an amino acid sequence represented by SEQ ID NO: 215, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 214.
As a control for the cell permeable RUNX3 recombinant proteins, HR3, where a full-length RUNX3 is fused only to a nuclear localization sequence (NLS) derived from SV40 large T antigen and a histidine-tag (His-Tag) without any MTD, was constructed. The control protein has an amino acid sequence represented by SEQ ID NO: 241, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 240.
In order to construct a cell permeable RUNX3 recombinant protein by using one of a JO-57 MTD (MTD2), a JO-85 MTD (MTD3), a JO-13 MTD (MTD4) and a JO-108 MTD (MTD5), three full-length forms of a CP-RUNX3 recombinant construct for each MTD were constructed.
Referring to
In order to prepare said full-length CP-RUNX3 recombinant proteins, PCR was carried out according to the same method as described in section <1-1> of Example 1 above. The forward and reverse primers for amplifying HM2R3 have nucleotide sequences represented by SEQ ID NOS: 253 and 243, respectively; those for amplifying HR3M2 have nucleotide sequences represented by SEQ ID NOS: 242 and 254, respectively; and those for amplifying HM2R3M2 have nucleotide sequences represented by SEQ ID NOS: 253 and 254, respectively.
Further, the full-length forms of a CP-RUNX3 recombinant construct being fused to a JO-85 MTD were as follows:
In order to prepare said full-length CP-RUNX3 recombinant proteins, PCR was carried out according to the same method as described in section <1-1> of Example 1 above. The forward and reverse primers for amplifying HM3R3 have nucleotide sequences represented by SEQ ID NOS: 255 and 243, respectively; those for amplifying HR3M3 have nucleotide sequences represented by SEQ ID NOS: 242 and 256, respectively; and those for amplifying HM3R3M3 have nucleotide sequences represented by SEQ ID NOS: 255 and 256, respectively.
Further, the full-length forms of a CP-RUNX3 recombinant construct being fused to a JO-13 MTD were as follows:
1) HM4R3, where a JO-13 MTD is fused to the N-terminus of a full-length RUNX3;
In order to prepare said full-length CP-RUNX3 recombinant proteins, PCR was carried out according to the same method as described in section <1-1> of Example 1 above. The forward and reverse primers for amplifying HM4R3 have nucleotide sequences represented by SEQ ID NOS: 257 and 243, respectively; those for amplifying HR3M4 have nucleotide sequences represented by SEQ ID NOS: 242 and 258, respectively; and those for amplifying HM4R3M4 have nucleotide sequences represented by SEQ ID NOS: 257 and 258, respectively.
Further, the full-length forms of a CP-RUNX3 recombinant construct being fused to a JO-108 MTD were as follows:
In order to prepare said full-length CP-RUNX3 recombinant proteins, PCR was carried out according to the same method as described in section <1-1> of Example 1 above. The forward and reverse primers for amplifying HM5R3 have nucleotide sequences represented by SEQ ID NOS: 259 and 243, respectively; those for amplifying HR3M5 have nucleotide sequences represented by SEQ ID NOS: 242 and 260, respectively; and those for amplifying HM5R3M5 have nucleotide sequences represented by SEQ ID NOS: 259 and 260, respectively.
Each of the PCR amplified DNA fragments was subcloned into a pGEM-T Easy vector, followed by cloning into a pET-28(+)a vector according to the same method as described in section <1-1> of Example 1 above, to thereby obtain expression vectors for expressing cell permeable RUNX3 recombinant proteins. The successful insertion of the recombinant fragment into the pGEM-T Easy and pET-28(+)a vectors is confirmed in
The thus obtained expression vectors for expressing cell permeable RUNX3 recombinant proteins were designated pHM2R3, pHR3M2, pHM2R3M2, pHM3R3, pHR3M3, pHM3R3M3, pHM4R3, pHR3M4, pHM4R3M4, pHM5R3, pHR3M5, and pHM5R3M5, respectively.
Among them, the E. coli transformants DH5α/HM2R3 and DH5α/HM3R3 obtained by transforming E. coli DH5α with each of the expression vectors pHM2R3 where a JO-57 MTD is fused to the N-terminus of a full-length RUNX3 and pHM3R3 where a JO-85 MTD is fused to the C-terminus thereof were deposited on Oct. 29, 2008 in accordance with the Budapest Treaty under accession numbers KCTC-11408BP and KCTC-11409BP, respectively, with the Korean Collection for Type Cultures (KCTC), Korea Research Institute of Bioscience and Biotechnology (KRIBB), 52, Oun-Dong, Yusong-Ku, Taejon 305-333, Republic of Korea.
The results of sequencing analysis are as follows:
As for the full-length forms of the cell permeable RUNX3 recombinant protein constructed by using a JO-57 MTD as described above, HM2R3 has an amino acid sequence represented by SEQ ID NO: 217, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 216; HR3M2 has an amino acid sequence represented by SEQ ID NO: 219, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 218; and HM2R3M2 has an amino acid sequence represented by SEQ ID NO: 221, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 220.
As for the full-length forms of the cell permeable RUNX3 recombinant protein constructed by using a JO-85 MTD as described above, HM3R3 has an amino acid sequence represented by SEQ ID NO: 223, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 222; HR3M3 has an amino acid sequence represented by SEQ ID NO: 225, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 224; and HM3R3M3 has an amino acid sequence represented by SEQ ID NO: 227, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 226.
As for the full-length forms of the cell permeable RUNX3 recombinant protein constructed by using a JO-13 MTD as described above, HM4R3 has an amino acid sequence represented by SEQ ID NO: 229, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 228; HR3M4 has an amino acid sequence represented by SEQ ID NO: 231, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 230; and HM4R3M4 has an amino acid sequence represented by SEQ ID NO: 233, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 232.
As for the full-length forms of the cell permeable RUNX3 recombinant protein constructed by using a JO-108 MTD as described above, HM5R3 has an amino acid sequence represented by SEQ ID NO: 235, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 234; HR3M5 has an amino acid sequence represented by SEQ ID NO: 237, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 236; and HM5R3M5 has an amino acid sequence represented by SEQ ID NO: 239, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 238.
The oligonucleotides as a forward and reverse primer set specific for each recombinant protein used in Examples <1-1> and <1-2> are summarized in Table 2 below.
To select the optimal bacterial strain for the expression of cell permeable RUNX3 recombinant proteins prepared in Example 1 above, the following experiments were carried out in E. coli BL21(DE3), BL21-Gold(DE3), BL21-CodonPlus(DE3) and BL21-Gold(DE3) pLysS strains (Stratagene, USA), all of which contain the LacI promoter.
First, each of the expression vectors pHM1R3, pHR3M1, pHM1R3M1, and pHR3 (control) was transformed into E. coli BL21(DE3), BL21-Gold(DE3), BL21-CodonPlus(DE3) and BL21-Gold(DE3) pLysS strains, respectively, according to the heat shock method. After the transformation, the cells were cultured in an LB agar plate containing 50 μg/ml of kanamycin. Colonies formed on the plate were grown in 1 ml of LB medium at 37° C. overnight, followed by culturing at 37° C. in 100 ml of LB medium with vigorous shaking until the optical density 600 (OD600) reached 0.5. IPTG (isopropyl-β-D-thiogalactoside) was then added thereto at a final concentration of 0.7 mM to induce the expression of the CP-RUNX3 recombinant proteins. Protein induction was prolonged for 3 hours at 37° C. The E. coli culture solutions were harvested by centrifugation at 13,000×g for 1 minute, resuspended in a sample loading buffer (125 mM Tris-HCl, 20% glycerol, 2% (3-mercaptoethanol, 0.04% bromophenol blue, 4% SDS, pH 6.8), and subjected to boiling at 100° C. for 5 minutes. The cell lysates were centrifuged at 13,000 rpm for 1 minute, so as to separate an insoluble fraction from a soluble fraction. The thus obtained soluble and insoluble fractions of CP-RUNX3 recombinant proteins expressed in the E. coli strain with IPTG were loaded on a SDS-PAGE gel.
As shown in
Each of the expression vectors pHR3 (control), pHM1R3, pHR3M1, pHM1R3M1, pHM2R3 and pHM3R3 was transformed into E. coli BL21 CodonPlus(DE3), selected as the optimal strain in section <2-1> of Example 2 above, according to the heat shock method, followed by culturing in an LB medium containing 50 μg/ml of kanamycin. After that, the cells transformed with the recombinant protein encoding gene were grown in 1 ml of LB medium at 37° C. overnight, followed by culturing at 37° C. in 100 ml of LB medium with vigorous shaking until the optical density 600 (OD600) reached 0.5. IPTG was then added thereto at a final concentration of 0.5 mM to induce the expression of the CP-RUNX3 recombinant proteins. Protein induction was prolonged for 3 hours at 37° C. The E. coli culture solutions were harvested by centrifugation at 13,000 rpm for 1 minute, resuspended in a a sample loading buffer (125 mM Tris-HCl, 20% glycerol, 2% β-mercaptoethanol, 0.04% bromophenol blue. 4% SDS, pH 6.8), and subjected to boiling at 100° C. for 5 minutes. The cell lysates were centrifuged at 13,000 rpm for 1 minute, so as to separate the insoluble fraction from the soluble fraction. The thus obtained soluble and insoluble fractions of CP-RUNX3 recombinant proteins expressed in the E. coli strain with IPTG were loaded on a SDS-PAGE gel.
As shown in
The inducible expression of cell permeable RUNX3 recombinant proteins in an E. coli system leads to the formation of insoluble aggregates, which are known as inclusion bodies. To completely solubilize these inclusion bodies, all of the above expressed proteins were denatured by dissolving them in SDS used as a strong denaturing agent.
First, the BL21 CodonPlus(DE3) strains transformed with each of the expression vectors pHM1R3, pHR3M1, pHM1R3M1, pHM2R3 and pHM3R3 were cultured in 1 l of an LB medium as described in Example 2. Each culture solution was harvested by centrifugation, gently resuspended in 100 ml of a washing buffer (100 mM Tris-HCl, 5 mM EDTA, pH 8.0) without forming bubbles, and subjected to standing for 15 minutes at room temperature. After to the cell suspension was added 0.1 g of sodium deoxycholate, the mixture was subjected to pippetting so as to uniformly mix and ultrasonication on ice using a sonicator equipped with a microtip. The cells were intermittently sonicated for 30 seconds, followed by cooling for 10 seconds, while setting the power to 27% of the maximum power. The total sonication time was 10 minutes. The cell lysates were centrifuged at 4° C., 8,000×g for 10 minutes, so as to separate the supernatant and the cell precipitate. The cell precipitate was resuspended in 100 ml of a washing buffer (100 mM Tris-HCl, 0.1% sodium dexoycholate, 5 mM EDTA, pH 8.0) without forming bubbles, and was centrifuged at 4° C., 8,000×g for 10 minutes, so as to separate the supernatant and the cell precipitate. After repeating said washing step twice or more, the separated cell precipitate was stored at −20° C. for 12 to 16 hours. After that, the cell precipitate was suspended in 30 in of a lysis buffer (50 mM Tris-HCl, 0.1% SDS, 1 mM DTT, pH 8.0) without forming bubbles, and subjected to ultrasonication on ice using a sonicator equipped with a microtip. The cells were intermittently sonicated for 30 seconds, followed by cooling for 10 seconds, while setting the power to 27% of the maximum power. The total sonication time was 5 minutes. The cell lysates were centrifuged at 4° C., 8,000 rpm for 10 minutes, so as to separate the supernatant and the cell precipitate. The supernatant was loaded onto a Ni-NTA agarose resin where nitrilotriacetic acid agarose was charged with nickel (Ni). The Ni-NTA agarose resin was equilibrated with the lysis buffer. The supernatant was allowed to absorb onto the resin by gently shaking using a rotary shaker for 1 hour or more. The resin absorbed with the inclusion bodies containing the recombinant protein was centrifuged at 4° C., 1,000×g for 5 minutes, to remove the reaction solution and washed with a lysis buffer (50 mM Tris-HCl, 0.1% SDS, 1 mM DTT, pH 8.0) once to remove nonspecific absorbed materials. After washing, the proteins absorbed to the resin were eluted with an elution buffer (containing 250 mM imidazol) with stirring for 1 hour or more at room temperature. The eluted proteins were analyzed with 12% SDS-PAGE gel electrophoresis, stained with Coomassie Brilliant Blue R by gently shaking, and destained with a destaining solution.
According to the results shown in
In order to quantitatively determine the cell permeability of the cell permeable RUNX3 recombinant proteins according to the present invention, flow cytometry was carried out by using the cell permeable RUNX3 recombinant proteins (HM1R3, HR3M1, HM1R3M1, HM3R3) on RAW 264.7 cells derived from mouse macrophage, as follows.
The cell permeable RUNX3 recombinant proteins purified in Example 3 above were labeled with FITC (fluorescein-5-isothiocyanate, Molecular Probe). The recombinant protein (2 to 20 mg) was mixed with 1 μl of FITC at a concentration of 333 mg/ml and reacted in a dark room at room temperature for 1 hour with gentle stirring. The reaction solution was subjected to a dialysis against DMEM at 4° C. for 1 day until the unreacted FITC was completely removed, thereby obtaining FITC-conjugated recombinant proteins. Thus obtained FITC-conjugated recombinant proteins were subjected to a Bradford protein assay to measure the protein concentration. As a result, each of the FITC-conjugated recombinant proteins was measured to have a concentration of about 1 μg/μl.
Meanwhile, RAW 264.7 cells were maintained in DMEM supplemented with 10% fetal bovine serum and 5% penicillin/streptomycin (500 mg/ml) and incubated at 37° C. in a humidified atmosphere of 5% CO2 in air. After the incubation, the cells were treated with 10 μM of each of the FITC-conjugated recombinant proteins prepared above, followed by further culturing them for 1 hour at 37° C. Subsequently, the cells were treated with trypsin/EDTA (T/E) to remove cell surface bound proteins, washed with cold PBS (phosphate buffered saline) three times, and then, subjected to flow cytometry analysis by using a CellQuest Pro software program of the FACS (fluorescence-activated cell sorting) Calibur system (Beckton-Dickinson).
Referring to the results shown in
To visualize the intracellular localization of human RUNX3 recombinant proteins delivered into a cell, NIH 3T3 cells (Korean Cell Line Bank, Seoul, Republic of Korea) were treated for 1 hour without (cell only) or with FITC (FITC only), or 10 μM FITC-conjugated recombinant proteins lacking kFGF4-derived MTD (HR3) or 10 μM FITC-conjugated recombinant proteins fused to a kFGF4-derived MTD (HM1R3, HR3M1, HM1R3M1, HM2R3, HM3R3), and visualized by confocal laser scanning microscopy. The NIH3T3 cells were maintained in DMEM supplemented with 10% fetal bovine serum, 5% penicillin/streptomycin (500 mg/ml) in 5% CO2 at 37° C. In order to preserve the FITC fluorescence of the recombinant protein, the glass slide was fixed in 10 μl of a mounting medium for 15 minutes before the observation. For a direct detection of FITC-conjugated recombinant proteins that were internalized, the cells were washed with PBS three times and counterstained with a nuclear fluorescent stain solution, propidium iodide (PI, Sigma-Aldrich, St. Louis, Mo.). The intracellular distribution of the fluorescence was determined at the middle of a single cell analyzed by a confocal laser scanning microscope using a normaski filter.
As shown in
In order to examine whether the cell permeable RUNX3 recombinant proteins according to the present invention exhibit cell permeability with respect to a tissue, the following experiment was performed.
In this experiment, 7-week old Balb/c mice (Central Lab. Animal Inc., Seoul) were used. The mice were administered with 200 μg of the FITC-conjugated RUNX3 recombinant protein (HM3R3) via intraperitoneal injection. Two hours later, the mice were sacrificed, and various tissue samples were extracted from the liver, kidney, spleen, lung, heart and brain. The extracted tissues were embedded in an OCT compound, freezed, and then sectioned with a microtome to have a thickness of 14 μm. The tissue specimens were mounted on a glass slide and observed with a confocal laser scanning microscope. In order to preserve the FITC fluorescence of the recombinant protein, the glass slide was fixed in 10 μl of a mounting medium for 15 minutes before the observation.
As illustrated in
These results obtained in sections <4-1> to <4-3> of Example 4 above demonstrate that the cell permeable RUNX3 recombinant proteins according to the present invention can be effectively used for transporting a tumor and metastasis suppressor RUNX3 into a target tissue as well as a target cell.
In order to confirm the cellular function of the cell permeable RUNX3 recombinant proteins according to the present invention, western blot analysis was carried out on cancer cell lines as follows.
MKN 28 and NCI-N87 cells, gastric cancer cell lines used in this experiment, were purchased from Korean Cell Line Bank (Seoul, Republic of Korea). Each of MKN 28 and NCI-N87 cells was maintained in a RPMI 1640 medium (L-glutamine 300 mg/l, 25 mM HEPES and 25 mM NaHCO3 89.3%) supplemented with 9.8% heat inactivated FBS and 1% penicillin/streptomycin in a 5% CO2 incubator at 37° C. After 2 ml of the RPMI 1640 was added to each well of a 6-well plate, MKN 28 and NCI-N87 cells were inoculated thereto. The well plate was incubated at 37° C. for 1 day, followed by culturing in a serum-free medium, so as to grow the cells in the same cell cycle phase while the cells are adhered to the well plate. After removing the medium, the MKN 28 and NCI-N87 cells adhered to the well plate were washed with cold PBS (phosphate-buffered saline). Subsequently, the cells were treated with each of the cell permeable RUNX3 recombinant proteins HM1R3M1, HM2R3 and HM3R3 and control protein HR3 at a concentration of 10 μM, and reacted in a 5% CO2 incubator at 37° C. for 1 hour. After the reaction was completed, the cells were washed twice with PBS, and then, cultured in a 5% CO2 incubator at 37° C. for 12 hours. After the cultivation was completed, the cells were resuspended in 200 μl of a lysis buffer (20 mM HEPES, pH 7.2, 1% Triton-X, 10% glycerol) and subjected to ultrasonication on ice for 30 minutes, to thereby obtain a cell lysate. The cell lysate was centrifuged at 4° C., 12,000 rpm for 20 minutes to separate the supernatant. The thus obtained supernatant was subjected to a Bradford protein assay to quantitatively measure the protein concentration. The recombinant protein was resuspended in a SDS-PAGE loading buffer at a concentration of 25 μM to prepare a cell lysate sample. The thus prepared cell lysate sample was heated at 90° C. for 5 minutes, and then, stored at −80° C. until use.
For the western blot analysis, p21Wafl/Cipl (21 kDa, Cell Signaling Technology), p27 (27 kDa, Santa Cruz Biotechnology), PCNA (36 kDa, Santa Cruz Biotechnology), cleaved caspase 3 (17/19 kDa, Cell Signaling), cyclin A (54 kDa, Santa Cruz Biotechnology) cyclin E (53 kDa, Santa Cruz Biotechnology), phospho-Rb (Ser807/811, 110 kDa, Santa Cruz Biotechnology) and VEGF (15 kDa, Santa Cruz Biotechnology) were used as primary antibodies, and goat anti-mouse IgG-HRP (Santa Cruz Biotechnology) and goat anti-rabbit IgG-HRP (Santa Cruz Biotechnology) were used as secondary antibodies. The cell lysate sample was applied to a SDS-PAGE at 100 V for 2 hours and transferred onto a polyvinylidene fluoride (PDVF) membrane at 100 V for 1 hour. In order to prevent the nonspecific interaction between the blotted proteins and unrelated antibodies, the PVDF membrane was blocked with 5% non-fat dry milk in TBS/T (10 mM Tris-Cl, pH 8.0, 150 mM NaCl, 0.05% Tween 20) at room temperature for 1 hour. After removing the blocking buffer, the PVDF membrane was washed with TBS/T, followed by incubation with each of the primary antibodies for 1 day at 4° C. After removing the primary antibody solution, the membrane was washed with TBS/T three times, and incubated with the secondary antibody for 1 hour at room temperature. After washing with TBS/T three times, the membrane was stained using an enhanced chemiluminescence (ECL) detection system (GE Healthcare Amersham UK) to visualize the antigen/antibody interaction.
As shown in
Further, as shown in
In particular, the HM3R3 recombinant protein where a JO-85 MTD was fused to its N-terminus strongly inhibited the cell cycle of the cultured cancer cells, suggesting that it can be effectively used as a cell cycle inhibitor capable of preventing tumor formation.
In order to examine the cellular function of the cell permeable RUNX3 recombinant proteins according to the present invention, the apoptosis-inducing effect of the recombinant protein was examined by cellular DNA content analysis as follows.
NCI-N87 (Korean Cell Line Bank) cells, a human gastric cancer cell line, were cultured in a RPMI 1640 medium (L-glutamine 300 mg/l, 25 mM HEPES, 25 mM NaHCO3 89.3%, heat-inactivated fetal bovine serum 9.8%, streptomycin/penicillin 0.9%) in a 5% CO2 incubator at 37° C. After 2 ml of the RPMI 1640 medium was added to each well of a 6-well plate, the NCI-N87 cells cultured above were inoculated thereto, and grown at 37° C. for 1 day. Each of the cell permeable recombinant proteins HM1R3M1, HM2R3 and HM3R3 and control protein HR3 was added to each well at a concentration of 5 μM, followed by culturing them in a serum-free medium for 1 hour. After washing the well plate with cold PBS twice, 2 ml of the RPMI 1640 medium was added to each well, and the well plate was further incubated for 0, 2, 4, and 8 hours, respectively. After that, the cells were washed with cold PBS twice, suspended in 200 μl of PBS, and gently soaked in 4 ml of 70% ethanol. The thus obtained cell suspension was kept on ice for 45 minutes and stored at −20° C. for 1 day. The cell suspension was treated with PI (40 μg/ml) and RNase A (100 μg/ml) and subjected to flow cytometry analysis to quantify the degree of apoptosis induced.
According to the results shown in
In order to examine the cellular function of the cell permeable RUNX3 recombinant proteins according to the present invention, the inhibitory effect on cancer cell migration of the recombinant protein was examined by a wound healing assay as follows.
MKN 28 and NCI-N87 (Korean Cell Line Bank) cells, human gastric cancer cell lines, were cultured in a RPMI 1640 medium (L-glutamine 300 mg/f, 25 mM HEPES, 25 mM NaHCO3 89.3%, heat-inactivated fetal bovine serum 9.8%, streptomycin/penicillin 0.9%) in a 5% CO2 incubator at 37° C. C. After 2 ml, of the RPMI 1640 medium was added to each well of a 6-well plate, the cells cultured above were inoculated thereto, respectively, and grown at 37° C. for 1 day. Each of the cell permeable recombinant proteins HM1R3M1, HM2R3 and HM3R3 and control protein HR3 was added to each well at a concentration of 10 μM, followed by culturing them in a serum-free medium for 1 hour. After the cells were washed with PBS twice, they were wounded with a sterile yellow tip, to thereby form a reference line that separated the confluent area from the bare area. To the cells was added 1 ml of a RPMI medium, followed by culturing in a 5% CO2 incubator at 37° C. for 24 hours. After that, the migration was quantified by counting the number of cells that migrated from the wound edge into the bare area with an inverted light microscope.
Referring to the results shown in
Further, according to the results shown in
In order to examine the in vivo function of the cell permeable RUNX3 recombinant proteins, the anticancer effect thereof was assessed by using an animal model as follows.
In this experiment, 7-week old Balb/c mice (Central Lab. Animal Inc., Seoul) were used, and sixteen mice were subdivided into 4 groups of 4 mice each. NCI-N87 cells, a human gastric cancer cell line, were administered daily to the right leg of the mouse via subcutaneous injection at a concentration of 1×107 cells by using a syringe (omnican, Germany, B. BRAUN). The mice bearing a tumor of 90 to 100 mm3 in size (width2× length/2) were selected by using a vernier caliper. Each of the cell permeable RUNX3 recombinant proteins HM2R3 (Group 3, 100 μg) and HM3R3 (Group 4, 100 μg) was administered daily to the mice at a concentration of 0.5 μg/ml via intraperitoneal injection for 26 days. As a control, 200 μl each of a vehicle (PRMI 1640 medium, Group 1) and MTD-lacking RUNX3 protein HR3 (Group 2) was administered daily to the mice via intraperitoneal injection for 26 days. During the administration for 26 days, the change in tumor size and body weight in the mouse of each group was monitored, and the results are shown in
According to the results shown in
In order to examine the durability of the in vivo anticancer effect of the cell permeable RUNX3 recombinant proteins (HM2R3 and HM3R3) after administration, each of the recombinant proteins was administered to the mice for 26 days according to the same method as described in section <6-1> of Example 7 above. After the administration was terminated, 2 mice were selected from each group, and their tumor size was observed for 7 days.
According to the results shown in
In order to examine the effect of inducing apoptosis in tumor tissues after the administration of the cell permeable RUNX3 recombinant proteins, an immunohistological analysis was performed on the same mouse model as used in Example 6.
In particular, the cell permeable RUNX3 recombinant proteins (HM2R3 and HM3R3), vehicle, and HR3 (control) were administered to the mice subdivided into four groups (4 mice per group) via subcutaneous injection for 26 days, respectively, according to the same method as described in Example 6. After that, the mice had undergone further observation for 5 days after the administration was terminated, and then, organ and tumor tissue samples were extracted therefrom. Each of the organ and tumor tissue samples was fixed in formalin and embedded in paraffin melted at 62° C. in an embedding center, to thereby prepare a paraffin block. The paraffin block was sliced with a microtome to have a thickness of 5 μm, where the slices were mounted on a slide glass and treated with xylene for 5 minutes three times to remove paraffin. Next, the glass slide was hydrated by successively treating with 100%, 100%, 95%, 70% and 50% ethanol each for 3 minutes, washed with water for 5 minutes. In order to induce antigen presentation from the tissue, the glass slide was trated with 0.05% trypsin/EDTA and stored at 37 t for 20 minutes. The glass slide was then washed with water for 5 minutes, treated with 1% hydrogen peroxide for 10 minutes, washed with water three times each for 5 minutes, and then, washed with TBS (Tris buffered saline) for 5 minutes. For blocking non-specific antigen binding, the glass slide was treated with a normal horse serum for 1 hour. The slide glass was incubated with p21 Wafl/Cipl (21 kDa, Cell Signaling Technology) and VEGF (15 kDa, Santa Cruz Biotechnology) as primary antibodies at 4° C. for 1 day, followed by washing with TBS buffer three times each for 5 minutes. The slide glass was incubated with the goat anti-mouse IgG-HRP (Santa Cruz Biotechnology) and a gaot anti-rabbit IgG-HRP (Santa Cruz Biotechnology) as secondary antibodies for 1 hour at room temperature, followed by staining with a DAB (diaminobenzidine tetrahydrochloride, Vector Laboratories, Inc) substrate for 2 to 3 minutes. Subsequently, the slide glass was washed with distilled water and subjected to counter-staining with hematoxylin. Finally, the glass slide was dehydrated by successively treating with 95%, 95%, 100%, and 100% ethanol each for 10 seconds and dewaxed by treating with xylene twice each for 10 seconds. And then, the glass slide was sealed with Canada balsam as a mounting medium and observed with an optical microscope.
Referring to the results shown in
In order to examine the effect of inducing apoptosis in tumor tissues after the administration of the cell permeable RUNX3 recombinant proteins, a TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling) assay was performed by using the same mouse model as described in Example 8.
In particular, the cell permeable RUNX3 recombinant proteins (HM2R3 and HM3R3), vehicle, and HR3 (control) were administered to the mice subdivided into four groups (4 mice per group) via subcutaneous injection for 26 days, respectively, according to the same method as described in Example 6. After that, the mice had undergone further observation for 5 days after the administration was terminated, and then, a tumor tissue sample was extracted therefrom. The glass slide was prepared by using the extracted tumor tissue sample according to the same method as described in Example 7. The glass slide was treated with xylene for 5 minutes twice, to thereby remove paraffin. It was then successively treated with 100% ethanol twice for 5 minutes, and 90%, 80% and 70% ethanol each for 3 minutes so as to dehydrate the tumor tissue, followed by incubation in PBS for 5 minutes. The glass slide was treated with 0.1% Trition® X-100 dissolved in a 0.1% sodium citrate solution for 8 minutes, and washed with PBS twice for 2 minutes. After a drop of TUNEL reaction buffer (50 μl, Roche, USA) was added to the glass slide, the glass slide was incubated in a humidified incubator at 37° C. for 1 hour, washed with PBS three times, and then, observed with a fluorescence microscope.
Referring to the results shown in
In order to examine the effect of inducing apoptosis in tumor tissues after the administration of the cell permeable RUNX3 recombinant proteins, the following histochemical assay was performed by using an ApopTag Peroxidase in situ Apoptosis Detection Kit (Chemicon, S7100).
In particular, the cell permeable RUNX3 recombinant proteins (HM2R3 and HM3R3), vehicle, and HR3 (control) were administered to the mice subdivided into four groups (4 mice per group) via subcutaneous injection for 26 days, respectively, according to the same method as described in Example 6. After that, the mice had undergone further observation for 5 days after the administration was terminated, and then, a tumor tissue sample was extracted therefrom. The glass slide was prepared by using the extracted tumor tissue sample according to the same method as described in Example 7. The glass slide was treated with xylene for 5 minutes twice, to thereby remove paraffin. It was then successively treated with 100% ethanol twice for 5 minutes, and 90%, 80% and 70% ethanol each for 3 minutes so as to dehydrate the tumor tissue, followed by incubation in PBS for 5 minutes. The glass slide was treated with 20 μg/ml, of proteinase K (Sigma) for 15 minutes, washed with distilled water, and then, treated with 3% H2O2 (vol/vol, in PBS) for 5 minutes, to thereby inhibit the activity of endogenous peroxidase. The glass slide was treated with an equilibration buffer for 10 seconds, followed by treating with a terminus dexoynucleotidyl transferase (TdT) at 37° C. for 1 hour. After the reaction was completed, the glass slide was treated with a stop buffer and washed. Next, the glass slide was treated with a DAB coloring agent for 5 minutes, and counterstained with methyl green. After the staining, the glass slide was dehydrated, sealed with a cover slip, and observed with an optical microscope.
According to the results shown in
In order to examine the change in protein expression pattern in the tumor tissue treated with the cell permeable RUNX3 recombinant protein according to the present invention, a microarray assay was performed as follows.
In particular, each of the cell permeable RUNX3 recombinant protein (HM3R3), vehicle and HR3 (control) was administered to the mice subdivided into four groups via subcutaneous injection for 26 days, and then left alone for 5 days after the administration was terminated, according to the same method as described in Example 6 above. Thirty one days after the administration was initiated, tumor tissue samples were extracted from the mouse of each group and freezed with liquid nitrogen. Total RNA was isolated from the tumor tissue by using a TRIZOL reagent (Invitrogen) according to the manufacturer's instruction, and treated with an RNase-free DNase (Life Technologies, Inc.), to thereby completely remove the remaining genomic DNA.
The thus isolated RNA was subjected to synthesis and hybridization of a target cRNA probe by using a Low RNA Input Linear Amplification kit (Agilent Technology) according to the manufacturer's instruction. In brief, 1 μg of total RNA was mixed with a T7 promoter specific primer and reacted at 65° C. for 10 minutes. A cDNA master mix was prepared by mixing a first strand buffer (5×), 0.1 M DTT, 10 mM dNTP mix, RNase-Out and MMLV-RT (reverse transcriptase), and added to the reaction mixture. The resulting mixture was reacted at 40° C. for 2 hours, followed by reacting at 65° C. for 15 minutes, to thereby terminate the reverse transcription and dsDNA synthesis. A transcription master mix was prepared by mixing a transcription buffer (4×), 0.1 M DTT, NTP mix, 50% PEG, RNase-Out, inorganic pyrophosphatase, T7-RNA polymerase and cyanine (3/5-CTP) according to the manufacturer's instruction. The thus prepared transcription master mix was added to the dsDNA reaction mixture and reacted at 40° C. for 2 hours so as to perform dsDNA transcription. The thus amplified and labeled cRNA was purified with a cRNA Cleanup Module (Agilent Technology) according to the manufacturer's instruction. The labeled target cRNA was quantified by using a ND-1000 spectrophotometer (Nanoprop Technologies, Inc.). After the labeling efficiency was examined, cRNA was mixed with a blocking agent (10×) and a fragmentation buffer (25×), and reacted at 60° C. for 30 minutes so as to carry out the fragmentation of cRNA. The fragmented cRNA was resuspended in a hybridization buffer (2×) and directly dropped on a Whole Human Genome Oligo Microarray (44K). The microarray was subjected to hybridization in a hybridization oven (Agilent Technology) at 65° C. for 17 hours, followed by washing according to the manufacturer's instruction (Agilent Technology).
The hybridization pattern was read by using a DNA microarray scanner (Agilent Technology) and quantified by using a Feature Extraction Software (Agilent Technology). Data normalization and selection of fold-changed genes were carried out by using a Gene Spring GX 7.3 soft wear (Agilent Technology). The average of the normalized ratio was calculated by dividing a normalized signal channel strength by a normalized control channel strength. Functional annotation for a gene was conducted by using a Gene Spring GX 7.3 software (Agilent Technology) according to the Gene Ontology™ Consortium (http://www.geneontology.org/index.shtml).
The results of the microarray analysis are summarized in
As described in Table 3 above, in case of the apoptosis-relating genes, the expressions of interleukin α (IL 1A) and semaphorin 6A (SEMA6A) were up-regulated by about 2.0-fold or more in the mouse group treated with the cell permeable RUNX3 recombinant protein compared to that treated with the control protein.
As described in Table 4 above, in case of the cell adhesion-relating genes, the expressions of protein phosphatase 2 regulatory (PPP2R1B), RhoGDP dissociation inhibitor Γ (ARHGHIG) and opioid binding protein (OPCML) were down-regulated by about 2.0-fold or more in the mouse group treated with the cell permeable RUNX3 recombinant protein compared to that treated with the control protein.
As described in Table 5 above, in case of the cell cycle regulation-relating genes, while the expressions of protein phosphatase 2 regulatory (PPP2R1B) and pleiotrophin (PTN) were down-regulated by about 2.0-fold or more, the expressions of GAS2L1 (growth arrest-specific 2 like 1) and VASH1 (vasohibin 1) were up-regulated by about 2.0-fold or more in the mouse group treated with the cell permeable RUNX3 recombinant protein compared to that treated with the control protein.
As described in Table 6 above, in case of the cell growth-relating genes, the expressions of c-JUN, insulin-like growth factor (IGF1), ribosomal protein S6 kinase (RPS6KA3) and CD28 were down-regulated by about 2.0-fold or more in the mouse group treated with the cell permeable RUNX3 recombinant protein compared to that treated with the control protein.
As described in Table 7 above, in case of the cell proliferation-relating genes, the expressions of CD28 and cholecystokinin-B/gastrin receptor were down-regulated by about 2.0-fold or more in the mouse group treated with the cell permeable RUNX3 recombinant protein compared to that treated with the control protein.
As described in Table 8 above, in case of defense immunity-relating genes, while the expressions of leukocyte immunoglobulin-like receptor (LILRB4) and CCDC34 (coiled-coil domain containing 34) were up-regulated by about 2.0-fold or more, the expression of CD28 was down-regulated by about 2.0-fold or more in the mouse group treated with the cell permeable RUNX3 recombinant protein compared to that treated with the control protein.
Although the invention has been described in detail for the purpose of illustration, it is understood that such detail is solely for that purpose, and variations can be made therein by those skilled in the art without departing from the spirit and scope of the invention which is defined by the following claims.
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/KR2008/006526 | 11/6/2008 | WO | 00 | 5/3/2010 |
| Number | Date | Country | |
|---|---|---|---|
| 60985765 | Nov 2007 | US |
